Skip to main content
    G

    Geron Corporation (GERN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.23
    +0.04 (+3.36%)

    Market Cap: $764.54M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    85%(33/39)
    Avg Surprise
    +10.34%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.01
    Range$-0.01 - $-0.01
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.01-100.0%
    60d ago$-0.01-100.0%
    30d ago$-0.01-100.0%
    7d ago$-0.01-100.0%
    Current$-0.01
    Revenue Consensus
    $61M
    Range$57M - $63M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.02
    Range$0.02 - $0.02
    1 analysts
    Revenue Consensus
    $70M
    Range$66M - $74M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.02---
    Sep 26EST
    		-$-0.01---
    Jun 26
    Reported Aug 5
    		$-0.02$-0.01-100.00%Miss+0.0%
    Mar 26
    Reported May 6
    		$-0.00N/A+75.50%Beat+83.7%
    Dec 25
    Reported Feb 25
    		$-0.02$-0.03+24.29%Beat+40.4%
    Sep 25
    Reported Nov 5
    		$-0.03$-0.03+0.00%Beat+25.0%
    Jun 25
    Reported Aug 6
    		$-0.02$-0.03+33.33%Beat+80.0%
    Mar 25
    Reported May 7
    		$-0.03$-0.04+25.00%Beat+66.7%
    Dec 24
    Reported Feb 26
    		$-0.04$-0.05+23.28%Beat+60.4%
    Sep 24
    Reported Nov 7
    		$-0.04$-0.08+50.00%Beat+50.0%
    Jun 24
    Reported Aug 8
    		$-0.10$-0.10+0.00%Beat-11.1%
    Mar 24
    Reported May 2
    		$-0.09$-0.09+0.00%Beat-28.6%
    Dec 23
    Reported Feb 28
    		$-0.09$-0.10+10.00%Beat+10.0%
    Sep 23
    Reported Nov 2
    		$-0.08$-0.10+20.00%Beat+20.0%
    Jun 23
    Reported Aug 3
    		$-0.09$-0.08-12.50%Miss-28.6%
    Mar 23
    Reported May 11
    		$-0.07$-0.10+30.00%Beat+22.2%
    Dec 22
    Reported Mar 16
    		$-0.10$-0.12+16.67%Beat+0.0%
    Sep 22
    Reported Nov 3
    		$-0.10$-0.09-11.11%Miss-25.0%
    Jun 22
    Reported Aug 11
    		$-0.07$-0.09+22.22%Beat+22.2%
    Mar 22
    Reported May 9
    		$-0.09$-0.10+10.00%Beat+0.0%
    Dec 21
    Reported Mar 10
    		$-0.10$-0.08-25.00%Miss-42.9%
    Sep 21
    Reported Nov 9
    		$-0.08$-0.09+11.11%Beat-33.3%
    Jun 21
    Reported Aug 16
    		$-0.09$-0.09+0.00%Beat-50.0%
    Mar 21
    Reported May 10
    		$-0.09$-0.08-12.50%Miss-12.5%
    Dec 20
    Reported Mar 11
    		$-0.07$-0.06-16.67%Miss+53.3%
    Sep 20
    Reported Nov 5
    		$-0.06$-0.06+0.00%Beat+25.0%
    Jun 20
    Reported Aug 6
    		$-0.06$-0.06+0.00%Beat+25.0%
    Mar 20
    Reported May 28
    		$-0.08$-0.12+33.33%Beat-60.0%
    Dec 19
    Reported Mar 12
    		$-0.15$-0.19+21.05%Beat-275.0%
    Sep 19
    Reported Nov 6
    		$-0.08$-0.13+38.46%Beat-166.7%
    Jun 19
    Reported Aug 1
    		$-0.08$-0.10+20.00%Beat-100.0%
    Mar 19
    Reported May 2
    		$-0.05$-0.05+0.00%Beat-25.0%
    Dec 18
    Reported Mar 7
    		$-0.04$-0.04+0.00%Beat+20.0%
    Sep 18
    Reported Nov 1
    		$-0.03$-0.05+40.00%Beat+25.0%
    Jun 18
    Reported Jul 31
    		$-0.04$-0.04+0.00%Beat+0.0%
    Mar 18
    Reported May 10
    		$-0.04$-0.05+20.00%Beat+20.0%
    Dec 17
    Reported Mar 16
    		$-0.05$-0.05+0.00%Beat+0.0%
    Sep 17
    Reported Nov 1
    		$-0.04$-0.05+20.00%Beat-
    Jun 17
    Reported Aug 9
    		$-0.04$-0.05+20.00%Beat-
    Mar 17
    Reported May 9
    		$-0.05$-0.05+0.00%Beat-
    Dec 16
    Reported Mar 1
    		$-0.05$-0.06+16.67%Beat-

    Key Metrics

    Valuation
    P/E Ratio-16.16EV/EBITDAN/A
    Price/FCF-0.01xFCF Yield-13932.86%
    Profitability
    Profit Margin-33.10%Operating Margin-22.00%
    ROE-28.30%ROIC-12.15%
    Financial Health
    Debt/Equity0.55xInterest Coverage-1.72x
    Current Ratio6.92xQuick Ratio5.16x
    Trading Statistics
    Beta0.61Avg Volume8.81M
    52-Week High$2.0152-Week Low$1.04

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.21
    SMA 20$1.24
    SMA 50$1.39
    SMA 200$1.44
    EMA 10$1.22
    EMA 20$1.25
    EMA 50$1.32
    EMA 200$1.39

    MACD

    Line: -0.05Signal: -0.05Hist: 0.01

    ADX

    ADX: 32.1+DI: 15.9-DI: 24.1

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down96.0
    PSAR$1.26

    Bollinger Bands

    Upper Band$1.31
    Lower Band$1.16
    %B Position1145%(Upper)
    Band Width0.46

    RSI (14-Day)

    Neutral
    42.3

    Momentum Oscillators

    Stoch %K36.7
    Stoch %D31.9
    Williams %R-40.0
    ROC (10d)1.7%
    Momentum0.02
    CCI (20d)-28.9
    MFI (14d)37.3

    Volatility Measures

    ATR (14d)$0.05(4.3%)
    StdDev (20d)0.04
    Hist Vol27.3%(Moderate)

    Volume Flow

    VWAP$1.22
    OBV-238.8M
    AD Line-253.6M
    CMF (20d)-0.049

    Volume Metrics

    Avg Vol (20d)8.6M
    Vol Ratio0.7x
    VWMA (20d)$1.24

    Pivot Points

    R3$1.24
    R2$1.22
    R1$1.21
    Pivot Point$1.19
    S1$1.17
    S2$1.15
    S3$1.14

    Advanced Oscillators

    TSI-27.63
    Ultimate Osc54.0
    KST-138.37

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$57.48M$51.84M$48.02M$47.23M$49.04M$39.60M$47.54M$28.27M$882,000$304,000$-193,000$164,000
    Cost of Revenue$9.24M$1.69M$1.31M$1.04M$1.19M$1.21M$783,000$456,000$17,000$0$241,000$0
    Gross Profit$48.24M$50.15M$46.71M$46.18M$47.85M$38.40M$46.75M$27.82M$865,000$304,000$-193,000$164,000
    Operating Expenses$60.74M$49.99M$72.25M$60.07M$60.30M$55.10M$66.80M$56.03M$70.20M$56.44M$54.31M$47.78M
    R&D$22.03M$14.96M$13.55M$21.07M$21.74M$15.08M$23.43M$20.15M$30.78M$29.37M$32.91M$29.43M
    SG&A$38.86M$35.42M$41.67M$39.00M$38.56M$40.02M$43.37M$35.88M$39.42M$27.07M$21.40M$18.35M
    Operating Income$-12,496,000$158,000$-25,540,000$-13,887,000$-12,454,000$-16,704,000$-20,050,000$-28,215,000$-69,333,000$-56,134,000$-54,289,000$-47,612,000
    Interest Income$2.97M$3.42M$4.04M$4.26M$4.66M$5.15M$5.16M$4.88M$5.33M$4.24M$4.60M$4.96M
    Interest Expense$7.15M$7.15M$7.30M$8.64M$8.52M$8.20M$10.41M$3.05M$3.32M$3.43M$2.32M$2.07M
    Income Before Tax$-16,680,000$-3,642,000$-28,862,000$-18,428,000$-16,375,000$-19,835,000$-25,352,000$-26,447,000$-67,383,000$-55,390,000$-51,973,000$-44,805,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-16,680,000$-3,642,000$-28,862,000$-18,428,000$-16,375,000$-19,835,000$-25,352,000$-26,447,000$-67,383,000$-55,390,000$-51,973,000$-44,805,000
    EBITDA$-12,583,000$-373,000$-26,496,000$-14,992,000$-13,682,000$-18,436,000$-27,186,000$-30,063,000$-70,803,000$-57,486,000$-56,476,000$-50,555,000
    EBIT$-12,505,000$84,000$-25,610,000$-14,048,000$-12,515,000$-16,787,000$-20,098,000$-28,278,000$-69,396,000$-56,196,000$-54,248,000$-47,704,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GERN

    News

    Geron stock trades 38.81 percent below its 52-week high

    Geron stock is trading 38.81 percent below its 52-week high, despite reporting a 11.70 percent increase in second-quarter revenue to USD 57.48 million. The company's Nasdaq quotation was USD 1.23, up 2.94 percent...

    ad-hoc-news.de•10/15/26•Neutral

    Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

    The article poses a question regarding whether Geron Corporation insiders breached their fiduciary duties to shareholders. It is a headline-only news item from PR Newswire. No further details are provided within the body...

    TradingView•10/13/26•Bearish

    Geron Corporation Announces Oral Presentations Highlighting

    Geron Corporation announced oral and poster presentations highlighting its drug imetelstat for lower-risk myelodysplastic syndromes (LR-MDS) at international hematology congresses in Europe and Asia. These presentations...

    GlobeNewswire•10/13/26•Bullish

    Long term debt to total assets ratio of Geron Corporation – HAN:GON

    This article provides financial data for Geron Corporation (HAN:GON) focusing on its long-term debt to total assets ratio. The data is presented within the TradingView platform...

    TradingView•10/12/26•Neutral

    Geron Corporation Announces Oral Presentation

    Geron Corporation announced an oral presentation at the European Hematology Association (EHA) 2022 Hybrid Congress. Dr. John Scarlett, Chairman and CEO, will provide an overview of imetelstat...

    Moomoo•10/12/26•Somewhat-Bullish

    GERN Valuation and Fair Value

    P/E
    -16.2x
    Forward P/E
    65.4x
    P/FCF
    -0.0x
    PEG
    -2.4x
    P/B
    0.0x
    See GNG's fair value

    GERN Profitability: Margins, ROIC and FCF

    Gross margin
    93.5%
    Operating margin
    -22.0%
    Net margin
    -33.1%
    ROIC
    -12.1%
    ROE
    -28.3%
    FCF margin
    -56.2%
    FCF yield
    -13932.9%

    GERN Competitors

    CompanyTicker
    Varex Imaging CorpVREX
    Candel Therapeutics IncCADL
    Corvus Pharmaceuticals IncCRVS
    Enhabit Inc.EHAB
    Ginkgo Bioworks HoldingsDNA
    Immix Biopharma IncIMMX
    Esperion Therapeutics IncESPR
    Collegium Pharmaceutical IncCOLL

    Sector: Healthcare

    GERN Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    1
    Buy
    3
    Hold
    1
    Sell
    0
    Strong Sell
    0

    GERN Bull Case vs Bear Case

    Bull case

    • GERN beat EPS estimates in 75.0% of its last 8 reported quarters.
    • GERN grew quarterly revenue 17.2% year over year.
    • 80.0% of GERN's analyst ratings are Buy or Strong Buy.

    Bear case

    • GERN has a -33.1% net profit margin.

    GERN Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    16.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.01
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About GERN

    Does GERN pay dividends?

    Geron Corporation (GERN) does not currently pay a regular dividend.

    What is GERN's market cap?

    Geron Corporation (GERN) has a market capitalization of $764.54M with a current stock price of $1.23.

    Related stocks

    Sector: Healthcare

    All stocks starting with G

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In